INDUSTRY

Migraine in the workplace

European survey on migraine in the workplace. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. Read de complete document in our Study section About the study of Migraine in the workplace The objective

Migraine in the workplace Read More »

European Migraine Day of Action with MEPS in the European Parliament

Each year, September 12th is the European Migraine Day of Action. Today, EMHA’s President and Executive Director have been invited by MEP Esteban Gonzalez Pons and MEP Dolors Montserrat to the European Parliament to discuss about how to better help the affected ones to give light to the disease and how to improve the life

European Migraine Day of Action with MEPS in the European Parliament Read More »

New drugs, decades in the making, are providing relief for migraines.

Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she

New drugs, decades in the making, are providing relief for migraines. Read More »

“Green light” to Lilly’s monoclonal antibody to migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes

“Green light” to Lilly’s monoclonal antibody to migraine Read More »

Lilly Receives Positive CHMP Opinion for Emgality

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least

Lilly Receives Positive CHMP Opinion for Emgality Read More »

Lilly’s Emgality Approved

INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available

Lilly’s Emgality Approved Read More »

Scroll to Top
Search
Close this search box.